21 October 2019
Biorelate launches AI-powered curation engine, Galactic, to combat the growing challenge of information overload in biomedicine.
Manchester, UK & San Diego, CA, 10 October 2019 – Biorelate, the AI company curating biomedical knowledge, today announces the launch of its proprietary tool for accelerated research intelligence, Galactic, at BioData World West 2019.
Early adopters include McCann Health Medical Communications, ApconiX and the UK’s Cell & Gene Therapy Catapult
The digitisation of information is transforming the biomedical industry, but there are major challenges associated with managing the ever-growing repositories of research being generated. Estimates suggest that over 80% of biomedical data is unstructured1, and with global scientific output doubling every nine years2 this issue is only getting worse.
Galactic uses artificial intelligence to auto-curate knowledge from over 30 million biomedical research text sources, to help make sense of the unstructured data and generate a clear view of the true state of research. Users can customise their experience by incorporating their own documents with publicly available data. Navigating the platform through Galactic’s tailored portals, users can find research, information, and hidden insights, and make hypotheses and predictions, while saving significant time and resources.
To better understand the problems currently faced by the research and development industry, Biorelate engaged early adopters from a variety of research positions. A collaboration with the McCann Health Global Scientific Council and the CMC Connect division of the McCann Health Medical Communications team focused on tackling issues with accessing information from the literature, including addressing the major pain points associated with systematic and pragmatic reviews.
Dr Alice Choi, COO of McCann Health Medical Communications and Executive Director, Global Scientific Council, commented: “We are passionate about understanding, curating and communicating scientific data in a timely, accurate, meaningful and compelling way. Working with the Biorelate team as a partner, as one of the early adopters of Galactic, we are exploring how we can harness AI to make this a more powerful process.”
Cell and Gene Therapy Catapult is at the forefront of the UK cell and gene therapy industry and has identified the potential of using AI and this platform within this space. The CGT Catapult team has helped in the optimisation of Galactic, making it a reliable source to track the latest developments in gene therapy across the UK. They will be the first users of the final product upon today’s launch.
Working with ApconiX, Galactic has been used in supporting Acuity Target Safety Assessments (TSAs) developed by project toxicologists. A recent report by ApconiX on assessing target safety concluded that the use of AI to access a comprehensive dataset provides an excellent starting point for the expert toxicologist to interpret the data, indicate key risks, and propose a risk-mitigation plan.3
Professor Ruth Roberts, Co-Founder and Director of ApconiX, commented: “The collaboration with Biorelate has been extremely productive and we look forward to working together on future developments.”
Dr Dan Jamieson, CEO and Founder of Biorelate, commented: “At Biorelate we’re committed to supporting future innovations by helping people make much better use of the growing archives of latent biomedical research. Galactic brings together a tremendous amount of hard work in making that a reality and we’re delighted to be launching at BioData World West in San Diego, home to such a thriving scientific community. I’d like to pay particular thanks to my team, our partners and early adopters for their prowess and sheer brilliance and I look forward to continuing together on the exciting journey ahead.”